Application of N-acetylglucosamine in The preparation of medicine for treating local injure or whole body syndrome due to self immune reaction

A technology of acetamido and autoimmunity, which is applied in the application field of medicine and can solve problems such as unsatisfactory effects

Inactive Publication Date: 2004-10-06
ARMY MEDICAL UNIV +2
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hormones bring many side effects when they are used, so supportive therapy is often used at present, but the effect is not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of N-acetylglucosamine in The preparation of medicine for treating local injure or whole body syndrome due to self immune reaction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1. The wave-promoting test of the compound of formula (I)

[0017] 1. Test materials and methods:

[0018] 1.1 Sample: pure compound of formula (I).

[0019] 1.2 Test material:

[0020] Strains: Proteus mirabilis should meet the following biochemical reaction characteristics: power (+), urease (+), lactose (-), glucose (+), H 2 S (-), phenylalanine deaminase (+).

[0021] Medium: modified LB medium (composition: 1% tryptone, 0.5% yeast extract, 1% sodium chloride, 0.1% glucose, 0.002% TTC, pH7.2-7.4).

[0022] 1.3 Test method:

[0023] Control sample: plant Proteus mirabilis in the center of the LB plate and culture at 37°C for 9 hours;

[0024] Test sample: Add the compound of formula (I) at a final concentration of 0.5% to the LB plate, plant Proteus mirabilis in the same way, and culture at 37° C. for 9 hours.

[0025] 2. Test results and evaluation:

[0026] In the control sample, there are concentric rings that continuously expand outwards at inte...

Embodiment 2

[0028] The toxicological test of embodiment 2. formula (I) compound

[0029] Carry out the toxicology test of formula (I) compound, comprise:

[0030] 1. Acute toxicology test: including oral, intravenous injection and maximum dose administration test;

[0031] 2. Ames test;

[0032] 3. Mouse bone marrow cell micronucleus test;

[0033] 4. Mouse sperm teratogenic test;

[0034] 5. Chromosomal aberration test of mouse testis;

[0035] 6. Chronic lethal test;

[0036] 7. Subchronic toxicity (90-day feeding) test;

[0037] 8. Traditional teratogenicity test;

[0038] Test conclusion shows: when formula (I) compound acute toxicity test dose exceeds 2g / kg, acute poisoning reaction does not yet occur; In long-term toxicity test, the highest dose has reached 1g / kg, through four weeks test observation, no toxic reaction occurs; In the reproduction test, mice were fed from a conventional dose of 7 mg / kg, and after three passages, it was proved that the compound of formula (I) ha...

Embodiment 3

[0039] Example 3. Cytological test for regulation of microheterogeneic changes

[0040] The conventional incomplete 1640 medium was used for cell culture, and B16 tumor cells (purchased from Shanghai Institute of Cell Biology Tumor Cell Bank) were inoculated. In the continuous culture for more than 48 hours, under the condition that the waste of cell metabolism affects the growth environment, the changes of the micro-heterogeneity of the cells and the control effect of N-acetylglucosamine on them were observed. After adding N-acetylglucosamine with a final concentration of 1g / 100ml in the culture medium, the number of cells increased steadily with the prolongation of culture time during the growth process. Control test cells could not proliferate in the same medium and under the same culture conditions in the absence of N-acetylglucosamine. The test shows that under the condition of the compound of formula (1), the cells can adjust the micro-heterologous changes of the cells ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of N-acetylaminoglucose in preparing the medicines for treating the local injury or general sympton caused by autoimmune reaction is disclosed.

Description

technical field [0001] The invention relates to the application of N-acetylglucosamine or pharmaceutically acceptable salt derivatives thereof in the preparation of medicines for treating local damage and / or systemic symptoms caused by autoimmune reactions. Background technique [0002] At present, there are two main methods of treatment for systemic symptoms caused by autoimmune reactions at home and abroad, such as fever, headache, dizziness, delirium, nausea, vomiting, and general malaise: 1. Immunosuppressant treatment such as cortisone 2. Supportive therapy. Hormones bring many side effects when they are used, so supportive therapy is often adopted at present, but the effect is not ideal. Therefore, there is still a need to develop drugs for the treatment and control of local damage and / or systemic symptoms caused by autoimmune reactions. [0003] The inventor established a model of biological wave growth in the study of biological wave theory, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7008A61P37/06
CPCA61K31/7008A61P5/14A61P25/04A61P29/00A61P37/02A61P37/06
Inventor 徐启旺刘俊康袁泽涛
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap